Novel Treatment Paradigms: Primary IgA Nephropathy
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024923016157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223787519246336 |
|---|---|
| author | Haresh Selvaskandan Jonathan Barratt Chee Kay Cheung |
| author_facet | Haresh Selvaskandan Jonathan Barratt Chee Kay Cheung |
| author_sort | Haresh Selvaskandan |
| collection | DOAJ |
| description | IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driven in large part by the acceptance of the surrogate clinical trial end point of proteinuria reduction by regulatory authorities for the accelerated approval of new therapies. Two drugs, targeted release formulation (TRF)-budesonide (nefecon) and sparsentan, have recently been approved under this scheme. Advancing insights into the pathophysiology of IgAN, including the roles of the mucosal immune system, B-cells, the complement system, and the endothelin system have driven development of therapies that target these factors. This review outlines current, recently approved, and emerging therapies for IgAN. |
| format | Article |
| id | doaj-art-1db64c96faa2412b8d9cc3ac66e2f61a |
| institution | OA Journals |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-1db64c96faa2412b8d9cc3ac66e2f61a2025-08-20T02:05:49ZengElsevierKidney International Reports2468-02492024-02-019220321310.1016/j.ekir.2023.11.026Novel Treatment Paradigms: Primary IgA NephropathyHaresh Selvaskandan0Jonathan Barratt1Chee Kay Cheung2Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UKMayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UKMayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; Correspondence: Chee Kay Cheung, John Walls Renal Unit, Leicester General Hospital, Gwendolen Road, Leicester, LE4 5PW, UK.IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driven in large part by the acceptance of the surrogate clinical trial end point of proteinuria reduction by regulatory authorities for the accelerated approval of new therapies. Two drugs, targeted release formulation (TRF)-budesonide (nefecon) and sparsentan, have recently been approved under this scheme. Advancing insights into the pathophysiology of IgAN, including the roles of the mucosal immune system, B-cells, the complement system, and the endothelin system have driven development of therapies that target these factors. This review outlines current, recently approved, and emerging therapies for IgAN.http://www.sciencedirect.com/science/article/pii/S2468024923016157APRILBAFFclinical trialscomplementendothelinIgA nephropathy |
| spellingShingle | Haresh Selvaskandan Jonathan Barratt Chee Kay Cheung Novel Treatment Paradigms: Primary IgA Nephropathy Kidney International Reports APRIL BAFF clinical trials complement endothelin IgA nephropathy |
| title | Novel Treatment Paradigms: Primary IgA Nephropathy |
| title_full | Novel Treatment Paradigms: Primary IgA Nephropathy |
| title_fullStr | Novel Treatment Paradigms: Primary IgA Nephropathy |
| title_full_unstemmed | Novel Treatment Paradigms: Primary IgA Nephropathy |
| title_short | Novel Treatment Paradigms: Primary IgA Nephropathy |
| title_sort | novel treatment paradigms primary iga nephropathy |
| topic | APRIL BAFF clinical trials complement endothelin IgA nephropathy |
| url | http://www.sciencedirect.com/science/article/pii/S2468024923016157 |
| work_keys_str_mv | AT hareshselvaskandan noveltreatmentparadigmsprimaryiganephropathy AT jonathanbarratt noveltreatmentparadigmsprimaryiganephropathy AT cheekaycheung noveltreatmentparadigmsprimaryiganephropathy |